| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Eltrombopag |
| Brand | Revolade® |
| Indication | For the treatment of chronic immune thrombocytopenic purpura (ITP) |
| Assessment Process | |
| Full submission received from Applicant | 30/07/2010 |
| NCPE assessment completed | 05/11/2010 |
| NCPE assessment outcome | The review group do not recommend the reimbursement of eltrombopag under the High Tech Drug scheme |
| A new rapid review was commissioned by the HSE in December 2017 | |
| Rapid review commissioned | 04/12/2017 |
| Rapid review completed | 16/04/2018 |
| Rapid Review outcome | A full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies. |